I head up medicinal chemistry for 研究和早期开发 within the 心血管,肾脏和代谢 disease area. In this role I lead a team of over 60 medicinal chemists and oversee the strategic direction and prioritisations of the chemistry in our early disease area pipeline. I also sit on the AstraZeneca Global Chemistry Leaders forum to guide the direction of chemistry for the company.
I have a tremendously strong team so a major part of my role is to guide and support them and remove obstacles, so they can focus on the core project deliverables. I truly enjoy seeing people I work with develop and take on new challenges and succeed.
Over the past six years that I have led this team, 澳门第一赌城在线娱乐已经建立了一个强大的管道, expanded our capabilities into new modalities chemistry and developed an extensive collaboration network.
在我的职业生涯中, I have been the lead chemist or contributing chemist on six drug candidates, 包括13项发明专利. I am particularly proud of the inventorship of a FLAP inhibitor which is currently being evaluated in clinical trials. I led the chemistry from the very start of the programme until late lead optimisation. To present this molecule as a first-time disclosure at the American Chemical Society (ACS) Annual Meeting in 2018 was a special feeling.
I achieved my PhD at 哥德堡 University in organic chemistry, specialising in bio-catalyzed asymmetric oxidation and went on to do my Post Doc at The Scripps Research Institute in California with Nobel Prize laureate Prof. 巴里•沙普利斯. I was in the Sharpless lab when the Cu-catalyzed click reaction was discovered and it has been amazing to witness how it has impacted so many areas of science.
I am deeply passionate about drug design to help bring new medicines to patients, including how to g等l required features into one molecule. I also believe strongly in innovation at the interfaces of scientific areas – for example, 各种化学形态的综合, 靶向给药, machine learning for drug design and drugging RNA using small molecules.
电流的作用
2020
2019
2019
特色的出版物
Design of a small molecule that stimulates VEGFA informed from an expanded encyclopedia of RNA fold-small molecule interactions.
汉尼夫,刘霞 等. 化学性质. http://doi.org/10.1038/s41557-020-0514-4
A novel chemical series of 5-LO activating protein (FLAP) inhibitors for treatment of Coronary Artery Disease.
Lemurell米, Ulander J, Emtenäs H 等. 医学化学 (2019), 62, 4325−4349.
Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase-Activating-Protein (AZD5718) for Treatment of Coronary Artery Disease.
Pettersen D; Broddefal J, Emtenäs H 等. 医学化学 (2019), 62, 4312−4324.
New Modalities for Challenging Targets in Drug Discovery.
刘建军,刘建军,刘建军 等. 《澳门第一赌城在线娱乐》 International Edition (2017) 56(35):10294-10323.
发现AZD6642, an Inhibitor of 5-Lipoxygenase Activating Protein (FLAP) for the Treatment of Inflammatory Diseases.
Lemurell米,吴国强,吴国强 等. 医学化学 (2015), 58(2), 897-911
A new approach to osmium-catalyzed asymmetric dihydroxylation and aminohydroxylation of olefins.
安德森MA, Epple R, Fokin v 等. 《澳门第一赌城在线娱乐》 国际版(2002),41(3),472-475